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Serous cystadenoma is a common benign neoplasm that can be managed without surgery in asymptomatic patients provided
that the diagnosis is certain. We describe a patient, whose pancreatic cyst exhibited a radiological appearance distinct from that
of typical serous cystadenoma, resulting in diagnostic diﬃculties. CT and MRI showed a 10cm-polycystic tumor with upstream
dilatation of the main pancreatic duct (MPD), suggestive of intraductal papillary mucinous tumor (IPMT). Ultrasonographic
aspect and EUS-guided ﬁne-needle aspiration gave arguments for serous cystadenoma. ERCP showed a communication between
cysts and the dilated MPD, compatible with IPMT. The patient underwent left pancreatectomy with splenectomy. Pathological
examination concluded in a serous cystadenoma, with only a ductal obstruction causing proximal dilatation.
1.Introduction
Typical macroscopic characteristics of serous cystadenoma
of the pancreas consist of microcystic mass with a sponge-
like honeycomb aspect or central scar or both. The risk
of malignant transformation seems to be low even in the
long-term course [1]. Therefore, most authors advise that
patients who are asymptomatic can be closely followed
provided that diﬀerential diagnosis can be deﬁnitively made
with other potentially malignant cystic tumors, mainly
mucinous cystadenoma or intraductal papillary mucinous
tumor (IPMT) [2, 3]. But diagnostic diﬃculties may be
encountered in the macrocystic oligocystic form of serous
cystadenoma seen in 10% to 30% of cases [4, 5]. In this
paper, we present the rare case of a serous cystadenoma of
the pancreas causing obstruction and upstream dilatation of




of thyroidectomy was admitted to Lille University Hospital
for further evaluation of a large cystic mass in the distal
pancreas. She had complained of transient epigastric pain
one month before. Blood biochemical parameters showed
no pancreatitis and the tumor markers, mainly CEA and CA
19-9, were all within the normal limits. On admission, the
patient was asymptomatic and the pancreatic mass was not
palpable in the upper abdomen. Contrast-enhanced com-
puted tomography (CT) and magnetic resonance imaging
(MRI) showed a huge, well-deﬁned, multiloculated, cystic
mass, of 10cm in greatest dimension, replacing the entire
body and tail of the pancreas, and displaying multiple
calciﬁcations in its isthmic part (Figures 1 and 2). MRI also
showed an upstream dilatation of the main pancreatic duct
(MPD) to 16mm, with no dilatation of its distal part and no2 HPB Surgery
Figure 1: Preoperative computed tomography: presence of a well-
deﬁned multiloculated cystic mass in the body and tail of the
pancreas with central calciﬁcations.
abnormalityinthepancreatichead(Figure 2).BothMRIand
CT concluded in IPMT. By contrast, endoscopic ultrasonog-
raphy(EUS)showedacomponentofmicrocysticpatternand
concluded in a serous cystadenoma. EUS-guided ﬁne-needle
aspiration (FNA) was performed through the gastric wall in
order to analyze the cyst ﬂuid at biochemical and cytological
levels:concentrationofCEAwas0.2ng/mL,whilecytological
analysis was not contributory. Regarding the diagnostic
uncertainty, we performed an endoscopic retrograde cholan-
giopancreatography (ERCP) that showed a cystic dilatation
of the pancreatic branches communicating with the dilated
MPD suggestive of an IPMT (Figure 3). These results
prompted us to operate on the patient especially as she had
complained of abdominal pain. On exploratory laparotomy,
a huge multicystic tumour measuring 10cm in maximum
diameter was found, replacing the entire body and tail of
the pancreas and surrounding the splenic vessels. A distal
pancreatectomy combined with splenectomy was carried
out. The postoperative course was uneventful, and the
patient was discharged on day 9. Macroscopic examination
of the resected specimen showed a combination of large cysts
with several small cysts and central calciﬁcations (Figure 4).
There was no communication between the ducts and the
cysts, but a compression of the main pancreatic duct and
secondary branches by the cysts with upstream dilatation.
Microscopically, the cysts were lined by a single layer of
cuboidal epithelial cells with clear cytoplasm (Figure 5).
Histopathological examination was thus indicative of serous
cystadenoma of the pancreas. Six months after surgery, the
patient remains well and asymptomatic.
3. Discussion
Serous cystadenoma has 2 main morphologic patterns:
typicalone,seenin70%ofcases,displaysmicrocysticpattern
that is characterized by radiologically visible multiple cysts
measuring 2cmorsmaller, withoutcommunication with the
MPD [5–7]. The cystic spaces are separated by ﬁbrous septa
that can coalesce into a central scar that may calcify [8].
Figure 2: Magnetic resonance cholangiopancreatography: polycys-
tic mass of the left pancreas with upstream dilatation of the main
pancreaticduct(arrow).Thepancreaticheadshowsnoabnormality
and no dilatation of the MPD.
Figure 3: Endoscopic retrograde cholangiopancreatography: cystic
dilatation of the pancreatic branches communicating with the
dilated MPD suggestive of an IPMT.
Delayed imaging may occasionally be helpful for depiction
of the central scar [9]. In approximately 20% of patients,
serous cystadenomas are characterized by a honeycomb
pattern with numerous subcentimeter cysts which are not
radiologically distinguishable.
However, there are various features of serous cystadeno-
mas found on imaging studies which may lead to diagnos-
tic diﬃculties. Main atypical manifestations include cystic
tumor without microcystic pattern, cystadenoma with inter-
valgrowth,cystadenomacommunicatingwiththeMPD,and
giant tumors with ductal dilatation as seen in our patient
[5, 7]. Serous macrocystic adenoma that is composed of only
a few relatively large cysts (>2cm) or even a unilocular cyst
comprised 10% to 30% of the serous cystadenomas [10].
Several cases of serous oligocystic cystadenoma have been
misdiagnosedasmucinouscystadenomaandinappropriately
managed [11, 12]. Serous cystadenoma may display interval
growth, with larger tumors (≥4cm at presentation) more
likely to grow faster than small ones, up to 2cm per yearHPB Surgery 3
C0903942
Figure 4: Macroscopic appearance of the pancreatic cystic mass.
The lesion, which measures 10cm in greatest dimension, is made of
acombinationoflargecystswithseveralsmallcystsandreplacesthe
entire body and tail of the pancreas.
Figure 5: Microscopic appearance of the pancreatic cystic tumor.
Low-power microscopic view shows the simple cuboidal epithelial
cells with clear cytoplasm.
[7]. Communication with the MPD is not a usually ﬁnding
with serous cystadenomas and was found at ERCP in only
0.6% of cases in a series of 144 serous cystadenomas [13–
15]. Giant serous cystadenomas are also rare; this term
usually refers to a multicystic tumor larger than 10cm in
diameter in comparison with a mean tumor diameter of 4
to 5cm in most reports of serous cystadenoma [1, 16, 17]. In
some rare cases, the giant lesions produce a symptomatology
caused by the compression of the MPD, as seen in our
patient, or of adjacent structures such as bile ducts or
colon [1, 18]. Serous cystadenoma with ductal dilatation
is a rare cause of obstructive acute or chronic pancreatitis
[19]. When dilatation is observed, diﬀerential diagnosis with
IPMT may be diﬃcult. Interestingly, Kim et al. [2]h a v e
shown in 41 patients that diﬀuse or distal MPD dilatation
was exclusively observed in IPMT, whereas proximal MPD
d i l a t a t i o nt e n d e dt ob eo b s e r v e di ns e r o u sc y s t a d e n o m a .
Diﬀuse MPD dilatation in IPMT was mostly associated with
mucin secreted from the tumor, whereas proximal MPD
dilatation in serous cystadenoma was probably a mass eﬀect
due to extrinsic compression [2].
In most cases, the diagnosis of cystic pancreatic lesions
relies on CT and MRI. Nevertheless, when combined, their
diagnostic accuracy was less than 50% of cases in a recent
series of 70 cystic pancreatic lesions independently reviewed
by two blinded radiologists [13]. ERCP proves especially
useful in patients with IPMT, demonstrating mucin at
the ampulla and diﬀuse dilatation of the pancreatic ducts.
Nevertheless,inourcaseofcompressiveserouscystadenoma,
ERCP by showing a subsequent dilatation of the main pan-
creatic duct and secondary branches perplexed us. EUS has
been proposed as an ideal imaging technique for pancreatic
cystic lesions, as it oﬀers two means of diagnosis, that is,
high-resolution morphologic imaging and guidance for FNA
[20]. While EUS imaging alone has limitations regarding
deﬁnitive diagnosis, aspiration, and characterization of cyst
ﬂuid contents, that is, cytology, mucin, and tumor markers,
may provide incremental information. Although cytology
alone is rarely deﬁnitive, when such cytologic samples are
positive, the speciﬁcity is high [7]. Regarding cyst ﬂuid
tumor markers, the Cooperative Pancreatic Cyst Study [21]
reported that a CEA level greater than 192ng/mL had a
sensitivity, speciﬁcity, and diagnostic accuracy of 73%, 84%,
and 79%, respectively, for mucinous cystic lesions. A later
study identiﬁed cut-oﬀ levels of 5ng/mL to be highly speciﬁc
(95%) for nonmucinous cysts, as seen in our patient [22].
Consistently, cyst ﬂuid CEA of less than 5ng/mL for the
diagnosis of nonmucinous lesions had a sensitivity of 44%,
speciﬁcity of 96%, and diagnostic accuracy of 78% in a
recent study [23]. Although there are diﬀerences in CEA
levels by cyst type, there is also substantial overlap, and
this is particularly true for other cyst ﬂuid tumor markers
[24, 25]. False-negative results, in which there is no elevation
of CEA, are also possible but rarely seen [26]. Although
not performed in our centre, assessment of cyst mucin
may provide additional information, with the best proﬁle
obtained when both mucin and CEA are determined along
with cytology in a recent study [26].
Patients bearing a cystic pancreatic lesion are advised to
undergo resection based on deﬁned criteria: the presence of
symptoms, abnormal cyst aspiration ﬂuid, and radiologic
criteria suspicious for a mucinous neoplasm (main duct and
mixed type IPMN, cysts with associated mass, haemorrhage
or mural nodule, duct obstruction, or cyst rim calciﬁcations)
[27]. By contrast, for asymptomatic patients with benign-
appearing lesions, such as classic appearance of a serous
cystadenoma, observation alone seems appropriate [28].
Some authors have nevertheless advised resection for serous
cystadenomas measuring 4cm or more in maximal diameter
regardless of the presence or absence of symptoms, because
of greater median growth rate [7]. Regarding asymptomatic
lesions with uncertain diagnostic, it is important to identify
those lesions in need of resection and those that may be
safely monitored. It is in this cohort that FNA may be most
beneﬁcial. In those patients, EUS with FNA conﬁrmation of
a negative cytology and low ﬂuid CEA can further provide
evidence to support a monitoring approach and deferral of
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Figure 6: Diagnostic and management algorithm for cystic lesion of the pancreas.
distinction between low-risk pancreatic cysts such as serous
cystadenoma from high-risk neoplastic mucinous cysts
(mucinous cystadenoma and IPMT) cannot be made with
absolute certainty, laparotomy is inevitable, even for serous
cystadenomas incidentally discovered [16, 17]. Our algo-
rithm for diagnostic and management of pancreatic cystic
lesions is summarized in the Figure 6.
4. Conclusion
In conclusion, our case highlights an extremely rare case of
serous cystadenoma with compression of the main pancre-
atic duct. Despite the availability of high-quality imaging
techniques, uncertain diagnosis led us to perform left
pancreatectomy, although EUS with FNA were suggestive of
serous cystadenoma. Algorithm is then proposed to manage
cystic pancreatic lesions: (i) symptomatic lesions must be
removed and (ii) EUS with FNA is the key investigation for
asymptomatic lesions of uncertain imaging diagnosis.
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